Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline. “We have had a solid start to the year,” said Antony Mattessich, President and Chief Executive Officer. “Following a slowdown in cataract surgeries